Workflow
Cocrystal(COCP)
icon
Search documents
Cocrystal(COCP) - 2021 Q4 - Annual Report
2022-03-22 16:00
Part I [Business](index=4&type=section&id=Item%201.%20Business) Cocrystal Pharma develops novel antiviral therapeutics using a proprietary structure-based drug discovery platform - The company's core strategy is to discover and develop novel antiviral therapeutics for serious viral diseases, including coronavirus, influenza, hepatitis C, and norovirus, using its unique structure-based technologies[12](index=12&type=chunk) - Cocrystal's proprietary drug discovery platform integrates computational chemistry, X-ray crystallography, and medicinal chemistry to design small molecule therapeutics that target highly conserved regions of viral enzymes, aiming for high efficacy and a high barrier to resistance[14](index=14&type=chunk)[16](index=16&type=chunk) - The company's influenza A candidate, CC-42344, received regulatory clearance in Australia and began enrolling subjects for a Phase 1 clinical trial in March 2022[28](index=28&type=chunk) - For its coronavirus program, the company selected CDI-45205 as its lead protease inhibitor and is targeting a Phase 1 clinical study in 2022, with two other oral candidates, CDI-988 and CDI-873, selected for further development[32](index=32&type=chunk)[33](index=33&type=chunk)[34](index=34&type=chunk) - A key collaboration with Merck for influenza A/B antiviral agents has completed its research obligations, with Merck now solely responsible for further development, making Cocrystal eligible for up to **$156 million** in milestones plus royalties[58](index=58&type=chunk)[59](index=59&type=chunk) - The company has licensed broad-spectrum antiviral compounds from Kansas State University Research Foundation (KSURF) for norovirus and coronavirus, involving upfront fees, annual maintenance fees, and potential milestone payments up to approximately **$7.3 million** across two agreements[60](index=60&type=chunk)[63](index=63&type=chunk)[65](index=65&type=chunk) [Risk Factors](index=12&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks from financial losses, COVID-19, regulatory uncertainty, competition, and Nasdaq compliance - The company has a history of significant losses, with an accumulated deficit of **$259.1 million** as of December 31, 2021, and expects to continue incurring losses as it has no commercialized products[79](index=79&type=chunk)[93](index=93&type=chunk) - The COVID-19 pandemic has adversely affected operations, causing material delays and cost increases in R&D due to facility shutdowns, personnel illness, and supply chain issues with CROs and CMOs[81](index=81&type=chunk)[88](index=88&type=chunk) - The company is dependent on its collaboration with Merck for the development and commercialization of its Influenza A/B product candidates, and Merck can terminate the agreement at its discretion without cause, eliminating potential milestone payments (up to **$156 million**) and royalties[111](index=111&type=chunk)[114](index=114&type=chunk)[115](index=115&type=chunk) - The company faces intense competition in the COVID-19 therapeutic space from large pharmaceutical companies like Pfizer, Moderna, and Gilead, which possess substantially more resources and products in more advanced stages of development or already approved[107](index=107&type=chunk)[108](index=108&type=chunk)[109](index=109&type=chunk) - On November 16, 2021, the company was notified by Nasdaq of non-compliance with the minimum **$1.00** bid price requirement, with failure to regain compliance by May 16, 2022, potentially resulting in delisting of the common stock[86](index=86&type=chunk)[255](index=255&type=chunk) - As a result of a director being permanently enjoined from certain securities law violations, the company is unable to rely on certain registration exemptions like Rule 506, which could adversely affect its ability to raise capital through private placements[266](index=266&type=chunk) [Unresolved Staff Comments](index=43&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company has no unresolved staff comments from the Securities and Exchange Commission - Not applicable[294](index=294&type=chunk) [Properties](index=44&type=section&id=Item%202.%20Properties) Cocrystal Pharma leases office and laboratory spaces in Bothell, Washington, and office space in Miami, Florida - The company leases office and laboratory space in Bothell, Washington (expiring Jan 2024) and office space in Miami, Florida (expiring Aug 2024)[296](index=296&type=chunk)[297](index=297&type=chunk) [Legal Proceedings](index=44&type=section&id=Item%203.%20Legal%20Proceedings) The company is involved in a lawsuit with Liberty Insurance Underwriters Inc. and a pending petition for re-hearing in a dismissed legal proceeding - Liberty Insurance Underwriters Inc. filed a suit seeking a declaratory judgment of no insurance coverage for certain litigation and investigation costs, to which the company has filed a counterclaim, with the case set for trial in July 2022[299](index=299&type=chunk) - A lawsuit (Pederson II) filed by a former lawyer was dismissed and affirmed on appeal, with a petition for re-hearing by the Eighth Circuit pending as of the report date[301](index=301&type=chunk) [Mine Safety Disclosures](index=45&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[303](index=303&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=45&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq, has approximately 434 holders, and does not pay cash dividends - The company's common stock trades on The Nasdaq Capital Market under the symbol "COCP"[305](index=305&type=chunk) - The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future[306](index=306&type=chunk) [Selected Financial Data](index=45&type=section&id=Item%206.%20Selected%20Financial%20Data) As a smaller reporting company, Cocrystal Pharma is not required to provide selected financial data - Not required as the company is a smaller reporting company[308](index=308&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=46&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The company reported no revenue in 2021, an increased net loss, higher R&D expenses, and a strengthened cash position of **$55 million** Financial Highlights | Financial Metric | 2021 (in USD) | 2020 (in USD) | Change (in USD) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | **Revenue** | $0 | $2,014,000 | ($2,014,000) | Completion of research obligations under Merck agreement in 2020 | | **Net Loss** | ($14,185,000) | ($9,648,000) | ($4,537,000) | Increased R&D costs for COVID-19 and Influenza programs | | **R&D Expense** | $8,794,000 | $6,034,000 | $2,760,000 | Advancements in COVID-19 and influenza programs | | **G&A Expense** | $5,427,000 | $5,566,000 | ($139,000) | Reduced professional fees from conclusion of legal matters | Cash Flow Highlights | Cash Flow Activity | 2021 (in USD) | 2020 (in USD) | | :--- | :--- | :--- | | **Net Cash Used in Operating Activities** | ($12,719,000) | ($9,830,000) | | **Net Cash Used in Investing Activities** | ($52,000) | ($240,000) | | **Net Cash Provided by Financing Activities** | $38,466,000 | $35,662,000 | - The company raised a total of **$38.5 million** in net proceeds from common stock public financings during the year ended December 31, 2021[331](index=331&type=chunk) - As of March 23, 2022, the company had approximately **$55 million** in cash, which management expects will be sufficient to fund operations through 2023[328](index=328&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=50&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, this item is not applicable - Not applicable[344](index=344&type=chunk) [Financial Statements and Supplementary Data](index=50&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) Consolidated financial statements for 2021 and 2020 are presented, with an unqualified audit opinion and Goodwill Impairment Assessment identified as a critical audit matter - The independent registered public accounting firm, Weinberg & Company, issued an unqualified audit opinion on the consolidated financial statements[348](index=348&type=chunk) - The auditor identified the Goodwill Impairment Assessment as a critical audit matter due to the significant management judgment required in developing the fair value measurement of the reporting unit, which has a net balance of **$19.1 million**[352](index=352&type=chunk)[353](index=353&type=chunk) Balance Sheet Highlights (in thousands) | Balance Sheet Highlights | Dec 31, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | Cash | $58,705 | $33,010 | | Total Assets | $79,392 | $54,242 | | Total Liabilities | $1,843 | $1,737 | | Total Stockholders' Equity | $77,549 | $52,505 | Statement of Operations Highlights (in thousands) | Statement of Operations Highlights | Year Ended Dec 31, 2021 | Year Ended Dec 31, 2020 | | :--- | :--- | :--- | | Collaboration Revenue | $0 | $2,014 | | Research and Development Expense | $8,794 | $6,034 | | Net Loss | ($14,185) | ($9,648) | | Loss Per Share (basic and diluted) | ($0.16) | ($0.17) | Part III [Directors, Executive Officers, Corporate Governance, Compensation, Security Ownership, and Certain Relationships](index=79&type=section&id=Items%2010-14) Information for Items 10-14 is incorporated by reference from the company's definitive proxy statement - Information for Items 10, 11, 12, 13, and 14 is incorporated by reference from the company's definitive proxy statement to be filed within 120 days of December 31, 2021[489](index=489&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=80&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section provides an index of all exhibits filed with the Form 10-K, covering corporate governance and material contracts - The report includes an index of exhibits filed, such as corporate governance documents, material contracts, and officer certifications[492](index=492&type=chunk)[494](index=494&type=chunk) [Form 10-K Summary](index=81&type=section&id=Item%2016.%20Form%2010-K%20Summary) This item is not applicable - Not applicable[497](index=497&type=chunk)
Cocrystal Pharma (COCP) Investor Presentation - Slideshow
2022-03-12 16:03
Pipeline Programs - Cocrystal Pharma is advancing programs targeting high-value antiviral drug targets, including SARS-CoV-2 and its variants, pandemic and seasonal influenza A, and norovirus gastroenteritis[5] - The company plans to initiate Phase 1 trials for a COVID-19 oral protease inhibitor and CDI-45205 lead molecule in 2022[7] - Phase 1 subject enrollment for Influenza A CC-42344 (oral administration) is expected to begin in 1Q22[7] - Preclinical lead selection for the norovirus program is planned for 2022-2023[8] Technology and Collaboration - Cocrystal's proprietary drug discovery platform technology aims to develop first- and best-in-class broad-spectrum antiviral drugs[4] - The Merck collaboration for influenza A/B therapeutic has the potential for up to $156 million in milestone payments plus royalties[7, 28] Market and Financials - The company is targeting large, global markets for the treatment of acute and pandemic viral diseases[7, 45] - As of September 30, 2021, Cocrystal Pharma had approximately $616 million in cash and equivalents[44] - The company's market capitalization is approximately $52 million, with 975 million common shares outstanding[44] Disease Burden - Worldwide, influenza causes 1 billion cases, 3-5 million severe illnesses, and up to 650,000 deaths annually[24] - Norovirus is responsible for approximately 685 million infections annually worldwide, costing an estimated $60 billion[31] - An estimated 58 million people worldwide have chronic hepatitis C virus infection, with about 15 million new infections occurring per year[36]
Cocrystal(COCP) - 2021 Q3 - Quarterly Report
2021-11-14 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 COCRYSTAL PHARMA, INC. (Exact name of registrant as specified in its charter) | --- | --- | |------------------------------|---- ...
Cocrystal Pharma (COCP) Investor Presentation - Slideshow
2021-09-17 20:03
C@CRYSTAL Potent antivirals to combat some of the most serious diseases facing humanity September 2021 Nasdaq: COCP www.cocrystalpharma.com 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the development pipeline; expected results of our collaboration with Merck Sharp & Dohme Corp ...
Cocrystal(COCP) - 2021 Q2 - Quarterly Report
2021-08-15 16:00
[Part I – FINANCIAL INFORMATION](index=4&type=section&id=Part%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) Overview of the company's financial performance and position for the six months ended June 30, 2021, highlighting key statements and management analysis [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Presents the company's financial position, operations, equity, and cash flows for the six months ended June 30, 2021, showing increased net loss and cash [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets increased to **$87.4 million** by June 30, 2021, driven by a significant rise in cash, with stockholders' equity growing to **$84.7 million** Condensed Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | June 30, 2021 (unaudited) | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $67,062 | $33,010 | | Total current assets | $67,337 | $34,015 | | Total assets | $87,417 | $54,242 | | **Liabilities & Equity** | | | | Total current liabilities | $2,379 | $1,358 | | Total liabilities | $2,669 | $1,737 | | Total stockholders' equity | $84,748 | $52,505 | | Total liabilities and stockholders' equity | $87,417 | $54,242 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) No collaboration revenue for the three and six months ended June 30, 2021, with a widened net loss of **$6.6 million** for the six-month period Condensed Consolidated Statements of Operations (in thousands, except per share data) | Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | :--- | :--- | | Collaboration revenue | $- | $554 | $- | $1,015 | | Research and development | $2,747 | $1,976 | $4,324 | $3,259 | | General and administrative | $1,081 | $2,028 | $2,242 | $3,167 | | Loss from operations | $(3,828) | $(3,450) | $(6,566) | $(5,411) | | Net loss | $(3,821) | $(3,495) | $(6,559) | $(5,485) | | Net loss per share | $(0.04) | $(0.07) | $(0.08) | $(0.12) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Stockholders' equity increased to **$84.7 million** by June 30, 2021, primarily due to **$38.5 million** in net proceeds from common stock sales - The sale of 26 million shares of common stock in the second quarter of 2021 provided net proceeds of **$36.4 million**, significantly boosting stockholders' equity[15](index=15&type=chunk) - Total stockholders' equity grew by **$32.2 million** in the first half of 2021, from **$52.5 million** to **$84.7 million**[15](index=15&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from financing activities significantly increased to **$38.5 million**, leading to a **$34.1 million** net increase in cash, totaling **$67.1 million** Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(4,394) | $(4,388) | | Net cash used in investing activities | $(40) | $(220) | | Net cash provided by financing activities | $38,486 | $16,505 | | Net increase in cash and restricted cash | $34,052 | $11,897 | | Cash and restricted cash at end of period | $67,112 | $19,365 | [Notes to the Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) Details the company's biopharmaceutical focus, completion of Merck collaboration, significant capital raises, ongoing litigation, and post-quarter share authorization increase - The company's primary research responsibilities under the Collaboration Agreement with Merck were completed in January 2021, leading to no collaboration revenue in the first six months of 2021[48](index=48&type=chunk) - In May 2021, the company closed an underwritten public offering of 26 million shares, receiving approximately **$36.4 million** in net proceeds[70](index=70&type=chunk) - The company is engaged in ongoing litigation with Liberty Insurance Underwriters Inc. and A.G.P./Alliance Global Partners, with outcomes that cannot be reasonably estimated[98](index=98&type=chunk)[101](index=101&type=chunk)[102](index=102&type=chunk) - Subsequent to quarter end, in August 2021, the company increased its authorized shares of common stock from 100 million to 150 million[106](index=106&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses pipeline advancements, Q2 2021 operating results with no revenue and increased net loss, and **$67.1 million** cash providing **36 months** of liquidity [Research and Development Update](index=21&type=section&id=Research%20and%20Development%20Update) The company is advancing its influenza, coronavirus, and norovirus programs, with a Phase 1 influenza study planned for Q3 2021 and an IND-enabling coronavirus study for H1 2022 - **Influenza:** The company's novel PB2 inhibitor, CC-42344, has completed preclinical IND-enabling studies, and a Phase 1 study is planned to start in the third quarter of 2021[111](index=111&type=chunk) - **Coronavirus:** The lead compound CDI-45205 demonstrated a strong synergistic effect with remdesivir and showed potent activity against multiple SARS-CoV-2 variants, with an IND-enabling study planned for the first half of 2022[115](index=115&type=chunk)[116](index=116&type=chunk) - **Norovirus:** The company expects to complete a proof-of-concept animal study for its norovirus inhibitors by the end of 2021[118](index=118&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Q2 2021 saw no revenue due to Merck collaboration completion, increased R&D expenses, decreased G&A expenses, and a net loss of **$3.8 million** Comparison of Operating Results (in thousands) | Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Change | | :--- | :--- | :--- | :--- | | Revenue | $- | $554 | $(554) | | Research & Development Expense | $2,747 | $1,976 | $771 | | General & Administrative Expense | $1,081 | $2,028 | $(947) | | Net Loss | $3,821 | $3,495 | $326 | [Liquidity and Capital Resources](index=24&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds **$67.1 million** in cash, sufficient for **36 months** of operations, bolstered by **$38.5 million** from financing activities in H1 2021 - The company had **$67.1 million** in cash as of June 30, 2021, and believes this is sufficient to maintain planned operations for at least the next **36 months**[134](index=134&type=chunk) - Net cash provided by financing activities was **$38.5 million** for the first six months of 2021, a significant increase from **$16.5 million** in the same period of 2020, primarily due to equity offerings[132](index=132&type=chunk) - In May 2021, an offering of 26 million shares of common stock generated approximately **$36.4 million** in net proceeds[138](index=138&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not applicable to the company as a smaller reporting company - The company stated that this item is not applicable[146](index=146&type=chunk) [Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management confirmed the effectiveness of disclosure controls and procedures as of June 30, 2021, with no material changes to internal controls - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective as of June 30, 2021[147](index=147&type=chunk) - No material changes were made to the company's internal controls over financial reporting during the quarter ended June 30, 2021[148](index=148&type=chunk) [Part II – OTHER INFORMATION](index=27&type=section&id=Part%20II%20%E2%80%93%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity sales, and exhibits, providing additional context beyond the financial statements [Legal Proceedings](index=27&type=section&id=Item%201.%20Legal%20Proceedings) No material changes to previously disclosed legal proceedings were reported during the period - There were no material changes to the legal proceedings previously disclosed in the company's 2020 Annual Report on Form 10-K[151](index=151&type=chunk) [Risk Factors](index=27&type=section&id=Item%201.A.%20Risk%20Factors) The company reported no new risk factors in this filing - The company did not report any new risk factors in this filing[152](index=152&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=27&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) All recent sales of unregistered equity securities have been previously reported - All recent sales of unregistered securities have been previously reported[153](index=153&type=chunk) [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) Lists all exhibits filed with or incorporated by reference into the Form 10-Q, including corporate governance and certification documents - The exhibits filed with this Form 10-Q include the Certificate of Incorporation, officer certifications (Rule 302 and Section 906), and XBRL data files[157](index=157&type=chunk)[160](index=160&type=chunk)
Cocrystal(COCP) - 2021 Q1 - Quarterly Report
2021-05-16 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transi ...
Cocrystal(COCP) - 2020 Q4 - Annual Report
2021-03-16 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [X] FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 OR [ ] T ...
Cocrystal Pharma (COCP) Investor Presentation -Slideshow
2021-03-12 19:39
NASDAQ: COCP cocrystalpharma.com C & CRYSTAL Investor Presentation March 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. ("Merck"), including the anticipated characteristics of the drug candidates developed as the result of this collaboration, expected funding by Merck of future research, developm ...
Cocrystal Pharma (COCP) Investor Presentation -Slideshow
2021-01-20 23:12
NASDAQ: COCP cocrystalpharma.com C & CRYSTAL Investor Presentation January 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. ("Merck"), including the anticipated characteristics of the drug candidates developed as the result of this collaboration, expected funding by Merck of future research, develo ...
Cocrystal(COCP) - 2020 Q3 - Quarterly Report
2020-11-13 21:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [X] Smaller reporting company [X] Emerging growth company [ ] Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ...